Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
Pfizer and Merck KGaA’s Bavencio, which won an FDA nod for Merkel cell carcinoma in March, has now been approved in Europe to treat that cancer.
The breast cancer med Ibrance has been a shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to lift the whole company.
Johnson & Johnson is not going down without a fight after suffering a stinging $417 million talc powder defeat last month.
New allegations painting the industry as “boys’ club” are raised in a lawsuit by a former vice president of California-based Synthetic Genomics.
Leerink Partners says Amazon is already in talks with PBMs as it eyes the drug business, posing a larger threat to pharma than some might realize.
Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.
Roche has struck a deal to unload a plant in Spain to Recipharm, a move that will save 200 jobs as it sheds unneeded small-molecule facilities.
Big Pharma expanded in emerging markets by 6.1% last quarter, but GSK and Eli Lilly didn't reap as much growth as their peers
In a biosimilars case with blockbuster implications, Pfizer sued J&J, calling its strategy for fighting off Remicade biosimilars "anticompetitive.…